α-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate–activated protein kinase–peroxisome proliferator-activated receptor-γ coactivator-1α signaling in the skeletal muscle of aged mice

Yi Wang, Xiaojie Li, Yuming Guo, Lawrence Chan, Xinfu Guan

Abstract

Skeletal muscle mitochondrial dysfunction is associated with aging and diabetes, which decreases respiratory capacity and increases reactive oxygen species. Lipoic acid (LA) possesses antioxidative and antidiabetic properties. Metabolic action of LA is mediated by activation of adenosine monophosphate–activated protein kinase (AMPK), a cellular energy sensor that can regulate peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a master regulator of mitochondrial biogenesis. We hypothesized that LA improves energy metabolism and mitochondrial biogenesis by enhancing AMPK–PGC-1α signaling in the skeletal muscle of aged mice. C57BL/6 mice (24 months old, male) were supplemented with or without α-LA (0.75% in drinking water) for 1 month. In addition, metabolic action and cellular signaling of LA were studied in cultured mouse myoblastoma C2C12 cells. Lipoic acid supplementation improved body composition, glucose tolerance, and energy expenditure in the aged mice. Lipoic acid increased skeletal muscle mitochondrial biogenesis with increased phosphorylation of AMPK and messenger RNA expression of PGC-1α and glucose transporter–4. Besides body fat mass, LA decreased lean mass and attenuated phosphorylation of mammalian target of rapamycin (mTOR) signaling in the skeletal muscle. In cultured C2C12 cells, LA increased glucose uptake and palmitate β-oxidation, but decreased protein synthesis, which was associated with increased phosphorylation of AMPK and expression of PGC-1α and glucose transporter–4, and attenuated phosphorylation of mTOR and p70S6 kinase. We conclude that LA improves skeletal muscle energy metabolism in the aged mouse possibly through enhancing AMPK–PGC-1α–mediated mitochondrial biogenesis and function. Moreover, LA increases lean mass loss possibly by suppressing protein synthesis in the skeletal muscle by down-regulating the mTOR signaling pathway. Thus, LA may be a promising supplement for treatment of obesity and/or insulin resistance in older patients. © 2010 Published by Elsevier Inc.

1. Introduction

Obesity and related metabolic syndrome continue to be a major public health problem in the developed world. Both obesity and insulin resistance increase with aging, which is associated with reduced mitochondrial mass and function, leading to a defective energy homeostasis [1-3]. A substantial decline in mitochondrial oxidative capacity in the skeletal muscle may contribute to the whole-body aging process [1]. A reduction in respiration rate and mitochondria biogenesis accounts for a defective energy expenditure, which predisposes to obesity, type 2 diabetes mellitus, and other metabolic consequences [4]. Energy metabolism in the skeletal muscle is finely regulated in healthy subjects; however, such regulation may be impaired in aging and diabetes [5]. The mechanisms that regulate body composition and energy homeostasis are not fully understood.
Nutrient supplementation has been applied to slow down the aging process and improve the quality of life. Supplemented lipoic acid (LA) [1], an essential cofactor in mitochondrial dehydrogenase complexes, might protect against aging-related mitochondrial dysfunction [6,7] and increases glucose utilization in type 2 diabetes mellitus in vivo [8,9]. Recently, LA has been shown to induce body weight (BW) loss by inhibiting hypothalamic adenosine monophosphate–activated protein kinase (AMPK) activity, resulting from suppressed food intake and stimulated energy expenditure [10]. In addition, LA treatment combined with acetylcarnitine increases ambulatory activity in aged rats [11] and improves mitochondrial function with attenuated oxidative damage [12]. Skeletal muscle is a key tissue and a major contributor to whole-body energy homeostasis in humans [13]. However, it is unknown whether LA supplementation increases mitochondrial biogenesis and energy metabolism in skeletal muscle of aged mice.

Adenosine monophosphate–activated protein kinase is a highly conserved cellular energy sensor. It appears as an intracellular fuel gauge that is activated by a drop in the adenosine triphosphate to AMP ratio [14]. One mechanism by which activated AMPK stimulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis in skeletal muscle is by increasing glucose transporter–4 (GLUT-4) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) expression [15-17]. Furthermore, metformin treatment in type 2 diabetes mellitus activates AMPK, leading to enhanced glucose disposal in skeletal muscle [18]. Interestingly, the increase in AMPK activity results in suppressed skeletal muscle protein synthesis. Lipoic acid has been reported to increase AMPK activity in skeletal muscles in diabetes-prone obese rats and in C2C12 myotubes, which is accompanied by improved glucose metabolism and fatty acid oxidation [19,20]. Previous studies focused on LA-mediated antioxidative protective effects in aged mice [21,22], although its metabolic effects in energy metabolism are also evident in obese and/or diabetic mice [19,23]. Considering LA-mediated activation of AMPK, however, it is not known whether LA supplementation facilitates mitochondrial biogenesis and/or inhibits protein loss in aged mice. Therefore, we hypothesized that α-LA improves energy metabolism and mitochondrial biogenesis by enhancing AMPK–PGC-1α signaling in the skeletal muscle of aged mice. Our objectives in the present study are to determine whether LA-stimulated energy expenditure and protein loss are mediated by activating the AMPK–PGC-1α signaling pathway in the skeletal muscle of aged mice.

2. Methods

2.1. Experiment procedures

All experiments were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine. The C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) were fed ad libitum (standard rodent diet 2920; Harlan Teklad, Madison, WI) and given free access to water for 24 months. Individual male mice (at the age of 24 months) were provided with water supplemented with 0% (n = 10, as control group) or 0.75% α-LA (Sigma-Aldrich, St Louis, MO; n = 10, as treatment group) for 1 month. Body weight was recorded weekly. During the third week of treatment, food intake of mice was recorded daily for 1 week. After 1 month, the mice were killed under isoflurane anesthesia; and tissues were taken and frozen immediately in liquid nitrogen.

2.2. Body composition

During the fourth week of treatment, the mice in the fed status were anesthetized with isoflurane shortly; and then body composition was assessed in vivo by dual-energy x-ray absorptiometry (Lunar, Madison, WI). Body fat mass, lean mass, and bone density were analyzed using GE Lunar PIXImus software version 1.45 (Lunar).

2.3. Indirect calorimetry

During the fourth week of treatment, the mice were housed in individual chambers at 24°C ± 1°C with free access to food and water with/without 0.75% α-LA. Oxygen consumption and CO2 production were measured individually over 48 hours using the Columbus Instrument Oxymax System (Columbus Instruments, Columbus, OH). Two time points were sampled per hour. Energy expenditure was calculated using the formula provided by the manufacturer: energy expenditure (in kilocalories) = (3.815 + 1.232 VO2/ VCO2)·VO2.

2.4. Glucose tolerance test

Glucose tolerance test was performed during the fourth week of treatment. The mice were fasted for 16 hours and then were intraperitoneally injected with 2.0 g d-glucose per kilogram BW. Blood samples were taken at 0, 30, 60, and 90 minutes post–glucose administration. Blood glucose concentrations were measured by the glucose oxidase method using an Ultrasmart Glucose Meter (Life-Scan, Milpitas, CA). The area under the curve was calculated by an integration method.

2.5. RNA extraction and quantitative reverse transcriptase polymerase chain reaction

Total RNA was isolated from skeletal muscles (gastrocnemius muscles) and C2C12 cells using Trizol reagent (Invitrogen, Carlsbad, CA). RNA concentration was determined by NanoDrop 1000 (NanoDrop, Wilmington, DE). Reverse transcription was performed with 1 μg of RNA as template using SuperScript-III First-Strand Synthesis SuperMix kit (Invitrogen). An abundance of messenger RNA (mRNA) was quantified by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Primers and probes for PGC-1α were based on
were purchased from Cell Signaling Technology (Danvers, MA). As follows: forward, 5'-AGAGCGGGAGTCTGAAAGG-3'; reverse, 5'-CAGTTCTGTCGGCTTTTGTG-3'; probe, 5'-FAM-AGAGGAGATGCGCCTGT-GTAMRA-3'. Primers for GLUT-4 were based on GenBank accession no. NM_009204. As follows: forward, 5'-ATGCGCTGTGGCGTGGTTCTC-3'; reverse, 5'-ACCCATGCGGATATGACTGA-3'; probe, Sybergreen (Bio-Rad, Hercules, CA). The housekeeping gene 18S ribosomal RNA (rRNA) was not altered and thus used as an internal control in the study. Assays were performed in triplicate with an ABI Prism 7900 sequence detector (Applied Biosystems, Foster City, CA). Data were normalized to 18S rRNA (ΔΔC_T analysis).

2.6. Mitochondrial biogenesis

Mitochondrial biogenesis was determined by the ratio of mitochondrial DNA (mtDNA) to nuclear DNA (nDNA) contents quantified by real-time qPCR as described [24] assuming that nDNA remains constant. DNA was extracted from gastrocnemius muscles using UltraPure Phenol:Chloroform:isoamyl alcohol (25:24:1) (Invitrogen) followed by ethanol precipitation. For each DNA extract, the nuclear gene ribosomal protein large p0 and the mitochondrial gene cytochrome c oxidase subunit I (CoxI) were quantified individually by real-time qPCR. The specific primers used were as follows: p0 forward, 5'-GCCATTTCCGCTTCTGGAGGTTG-3'; p0 reverse, 5'-TGATCTGGTTGCTTTGGCAGATT-3'; CoxI forward, 5'-TCTACTATCGGAGCCTGAG-3'; and CoxI reverse, 5'-CTACTGATgCTCCTGCATGG-3'. Sybergreen was used as the probe. Data were normalized to the nuclear gene p0 DNA (ΔΔC_T analysis).

2.7. Protein extraction and Western blotting

Proteins were extracted from mouse gastrocnemius muscles and C2C12 cells. Muscle samples were homogenized on ice in radioimmunoprecipitation assay buffer (50 mmol/L Tris-HCl at pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride) and centrifuged at 10,000 for 30 minutes to differentiate in DMEM with 2% horse serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were allowed to differentiate in DMEM with 2% horse serum, 100 U/mL penicillin, and 100 μg/mL streptomycin for 3 days before treatment. Each treatment was repeated at least 3 times. After treatment as indicated, cells were washed twice with phosphate-buffered saline (PBS) before protein extraction with the radioimmunoprecipitation assay buffer or RNA extraction using Trizol reagent. The samples were then applied for Western blotting or real-time qRT-PCR.

2.8. Cell culture

The mouse myoblastoma C2C12 cells were obtained from the American Type Culture Collection (Manassas, VA). Cells were cultured in 6-well plates and maintained in Dulbecco modified Eagle medium (DMEM) containing 10% heat-inactivated fetal bovine serum (Invitrogen), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were allowed to differentiate in DMEM with 2% horse serum, 100 U/mL penicillin, and 100 μg/mL streptomycin for 3 days before treatment. Each treatment was repeated at least 3 times. After treatment as indicated, cells were washed twice with phosphate-buffered saline (PBS) before protein extraction with the radioimmunoprecipitation assay buffer or RNA extraction using Trizol reagent. The samples were then applied for Western blotting or real-time qRT-PCR.

2.9. [3H]-phenylalanine incorporation assay

Protein synthesis was determined by [3H]-phenylalanine incorporation assay [25]. In brief, C2C12 myotubes were grown in 6-well plates and changed to serum-free DMEM for 1 hour. C2C12 cells were then treated with α-LA at 1 mmol/L for 0.5, 2, or 24 hours. The stimulated cells were pulsed with 2 μCi/mL [3H]-phenylalanine (Sigma-Aldrich) for an additional 1 hour before harvest. After being washed with ice-cold PBS, the cells were scraped in 0.5 mL PBS, lysed, precipitated in 0.5 mL 20% trichloroacetic acid for 30 minutes on ice, and centrifuged at 10,000 for 15 minutes at 4°C. The pellets (precipitated proteins) were washed twice with 10% trichloroacetic acid and solubilized in 1 mL of 0.3 N NaOH for 1 hour. An aliquot (400 μL) was taken to determine the incorporated radioactivity by liquid scintillation counter (Beckman LS 3801, Fullerton, CA). Incorporation rate of [3H]-phenylalanine into total protein was expressed as disintegrations per minute per microgram protein mass and considered as protein synthesis.

2.10. [3H]-2-deoxyglucose uptake

Glucose uptake was determined by [3H]-2-deoxyglucose uptake with modification [26]. In brief, the [3H]-2-deoxyglucose uptake assay was performed with 6-well
plates. C2C12 myotubes were washed twice with DMEM, starved for 1 hour in serum-free DMEM, and then treated with \( \alpha \)-LA at 0 to 2 mmol/L. Cells were washed twice with Krebs–Ringer-Hepes (KRH) buffer (136 mmol/L NaCl, 4.7 mmol/L KCl, 1.25 mmol/L MgSO\(_4\), 1.25 mmol/L CaCl\(_2\), 20 mmol/L HEPES [pH 7.4]) without glucose and then assayed for the glucose uptake for 20 minutes at 0.5 mmol/L 2-deoxyglucose containing 1 \( \mu \)Ci/mL \([\text{3H}]\)-2-deoxyglucose (Amersham Biosciences). Nonspecific uptake was determined in the presence or absence of 5 \( \mu \)mol/L cytochalasin B. The cells were then solubilized in 1 mL of 0.3 N NaOH for 30 minutes before aliquots were taken for liquid scintillation counting. Measurements for glucose uptake were corrected for nonspecific uptake. Glucose uptake was expressed as disintegrations per minute per microgram protein mass.

2.11. Fatty acid \( \beta \)-oxidation

Fatty acid \( \beta \)-oxidation was determined by \([14\text{C}]\)-palmitate assay with modification [20,26]. C2C12 myotubes were grown in T-25 (25-cm\(^2\)) flasks, starved for 1 hour in serum-free DMEM, treated with \( \alpha \)-LA at 1 mmol/L for 6 hours, and then incubated with 2% bovine serum albumin and 0.4 mmol/L palmitate (plus 0.25 \( \mu \)Ci/mL \([14\text{C}]\)-palmitate [Amersham Biosciences]) for 1 hour and finally quenched by adding 2 mL of 6 mol/L HCl. The release of \( {14\text{C}} \)CO\(_2\) was trapped with 300 \( \mu \)L of 1 N NaOH. The trapped \( {14\text{C}} \)CO\(_2\) was determined by liquid scintillation counting.

Fig. 1. Lipoic acid improved body composition in the aged mice. A, Lipoic acid–treated mice had significantly lower final BW, fat mass, and lean mass than the control mice. B, Lipoic acid decreased body proportion of fat mass, but increased those of lean mass and bone mass. The data were analyzed by ANOVA and expressed as mean ± SEM (n = 10 per group). *\( P < .05 \) and **\( P < .01 \).

Fig. 2. Lipoic acid increased energy expenditure in the aged mice. Energy expenditure was measured with a 30-minute interval for 48 hours during the fourth week of LA treatment. A, Lipoic acid treatment increased O\(_2\) consumption compared with the control. B, Lipoic acid treatment increased CO\(_2\) production compared with the control. C and D, Energy expenditure and respiratory quotient were significantly higher in the LA-treated mice than those in the control mice during the light and dark cycles and at each sampling time point. Data were analyzed by repeated-measures ANOVA using the MIXED Procedure and expressed as means ± SEM (n = 10 per group). Note that significance symbols (** for \( P < .01 \)) are not shown.
2.12. Statistical analysis

Data (body composition, metabolic action, relative abundance of PGC-1α and GLUT-4 mRNA, relative abundance of mtDNA, and phosphorylation of proteins [AMPK, mTOR, P70S6, and 4E-BP1]) were analyzed by analysis of variance (ANOVA). Data (glucose concentration, O2 consumption, CO2 production, energy expenditure, and respiratory quotient) were analyzed by repeated-measures ANOVA using the MIXED Procedure (SAS Version 9.1; SAS Institute, Cary, NC), in which time of sampling was considered as the repeated effect. The relationship between α-LA dose and glucose uptake was fitted by an exponential regression model. Data were expressed as means ± SEM. P values < .05 or .01 were considered as statistical significance.

3. Results

3.1. Food intake and body composition

Daily intake of food was decreased (P < .05) by 18% in LA-treated mice (4.50 ± 0.30 g/d) compared with that (5.50 ± 0.30 g/d) in control mice. Over the period of 4 weeks, LA-treated mice lost (P < .05) BW of 5.27 ± 0.62 g (an equivalent of 15.8% of initial BW), whereas the control mice maintained their BW. The LA-treated mice had less adipose as well as lean mass (Fig. 1A). Therefore, the LA-treated mice had lower percentage of fat mass (Fig. 1B), but higher percentage of lean and bone mass.

3.2. Energy expenditure

The LA-treated mice had higher oxygen consumption (25.7 ± 0.35 mL/[kg0.75 min]) and CO2 production (23.9 ± 0.37 mL/[kg0.75 min]) than control mice (20.2 ± 0.35 and 17.2 ± 0.37 for O2 consumption and CO2 production, respectively) (Fig. 2A, B). Note that the difference between 2 groups was significant (P < .01) at individual time points in Fig. 2. Calculated energy expenditure was higher (7.64 ± 0.10 kcal/[kg0.75 h]) in the LA-treated mice than that (5.90 ± 0.10 kcal/[kg0.75 h]) in the control mice (Fig. 2C). Calculated respiratory quotient (ie, ratio of VCO2 to VO2) was higher in the LA-treated mice (0.93 ± 0.01) than in the control mice (0.85 ± 0.01). However, the difference for respiratory quotient was even more profound during the inactive (light) phase (Fig. 2D), indicating that LA stimulated more glucose utilization.

Fig. 3. Lipoic acid increased glucose tolerance in the aged mice. Glucose tolerance test was performed in the aged mice fasted for 16 hours. α-Glucose was administered intraperitoneally at 2 g/kg BW. A, After glucose load, the LA-treated mice had faster clearance than the control mice. However, no significant difference in basal levels of blood glucose was observed between the groups. B, There was a significant reduction in area under the curve in the LA-treated mice compared with that in the control mice. Data are presented as mean ± SEM (n = 6 per group). *P < .05 and **P < .01.

Fig. 4. Lipoic acid altered gene and protein expression in the skeletal muscle. A, Gene expression was measured by real-time qRT-PCR and expressed in terms of mRNA levels relative to 18s rRNA. The LA-treated mice had significantly elevated mRNA levels of PGC-1α and GLUT-4 in the skeletal muscle. B, Lipoic acid increased AMPK activation with decreased phosphorylation of mTOR and p70S6K; however, it did not significantly alter 4E-BP1 phosphorylation. Data are presented as mean ± SEM (n = 6 per group). *P < .05 and **P < .01.
3.3. Glucose tolerance

After glucose challenge in overnight-fasted mice, blood glucose concentrations were lower at 30 and 60 minutes (\(P < .01\)) during a glucose tolerance test in the LA-treated group than in the control group (Fig. 3A). Moreover, the area under curve was dramatically reduced by 47% (\(P < .01\)) in the LA-treated mice (Fig. 3B). These results suggest that LA not only stimulated glucose utilization, but also increased insulin sensitivity.

3.4. LA stimulates PGC-1\(\alpha\) and GLUT-4 gene expression in skeletal muscle

The mRNA abundance for PGC-1\(\alpha\) in the skeletal muscle was increased (\(P < .05\)) by 80.0% in the LA-treated mice compared with that in the control mice (Fig. 4A). Interestingly, the mRNA abundance for GLUT-4 in the skeletal muscle was increased (\(P < .01\)) by 105.0% in the LA-treated mice as well (Fig. 4A).

3.5. AMPK and mTOR signaling in the skeletal muscle

To determine whether AMPK accounts for LA-induced metabolic changes, we measured AMPK activation. The AMPK phosphorylation at Thr\(^{172}\) increased (\(P < .05\)) by 107.5% in response to LA treatment (Fig. 4B). In contrast to AMPK, the mTOR phosphorylation at Ser\(^{2448}\) was decreased by 31.5% and followed by a reduction of p70S6 kinase phosphorylation at Thr\(^{389}\) by 43.0%. However, there was no difference (\(P > .05\)) in 4E-BP1 phosphorylation at Thr\(^{37/46}\) between the 2 groups.

3.6. Mitochondrial biogenesis in the skeletal muscle

The relative abundance of mtDNA content (indicated by the mitochondrial gene CoxI) in the skeletal muscle was increased (\(P < .05\)) by 138% in the LA-treated mice compared with that in the control mice (Fig. 5).

3.7. Glucose uptake in C2C12 myotubes

We next evaluated LA-stimulated glucose uptake in C2C12 myotubes using [\(^{3}\)H]-deoxyglucose assay (Fig. 6A). Lipoic acid dose-dependently stimulated glucose uptake (\(P < .01\)). Significant stimulation was observed at 50 \(\mu\)mol/L (\(P < .01\)), and a maximal stimulation was achieved at 1000 \(\mu\)mol/L (\(P < .01\)). The LA dosage was estimated at 512.4 \(\mu\)mol/L for glucose uptake plateau.

3.8. Fatty acid \(\beta\)-oxidation in C2C12 myotubes

To further establish whether LA affects fatty acid \(\beta\)-oxidation, we quantified \(^{14}\)C-CO\(_2\) released from \(^{14}\)C-palmitate oxidation upon LA stimulation in C2C12 myotubes. Lipoic acid at 1000 \(\mu\)mol/L for 6 hours increased (\(P < .05\)) fatty acid \(\beta\)-oxidation by 33.2% compared with the control (Fig. 6B).

3.9. Protein synthesis in C2C12 myotubes

Lean mass was decreased in the LA-treated mice, which might be attributed to decreased protein synthesis and/or increased protein degradation. Therefore, we determined whether LA affected protein synthesis in C2C12 myotubes. The time course indicated that at least 24 hours of LA treatment (1 mmol/L) was needed to suppress protein synthesis (data not shown). Lipoic acid at 1000 \(\mu\)mol/L for 24 hours significantly inhibited (by 24\%, \(P < .01\)) [\(^{3}\)H]-
3.10. Gene expression in C2C12 myotubes

The mRNA abundance for PGC-1α was increased \((P < .01)\) by 2.1-folds in the LA-treated C2C12 myotubes compared with that in the control (Fig. 7). Furthermore, the mRNA abundance for GLUT-4 was increased \((P < .01)\) by 13.7-folds in the LA-treated C2C12 myotubes as well (Fig. 7).

3.11. AMPK and mTOR signaling in C2C12 myotubes

To further investigate LA-mediated metabolic action and cellular signaling, we explored LA-mediated effects in C2C12 myotubes. Lipoic acid treatment (100-2000 μmol/L for 2 hours; or 1000 μmol/L for 0.5, 2, and 24 hours) stimulated phosphorylation of AMPKα at Thr172 in a dose- and time-dependent manner in C2C12 myotubes (Fig. 8). The AMPK activation reached its maximum at 2 hours post–LA treatment. Phosphorylation of mTOR at Ser2448 and its downstream target P70S6 kinase at Thr389 was stimulated at 0.5 hour post–LA treatment, but was inhibited later on. This inhibited phosphorylation of mTOR and p70S6 kinase was correlated in a time-dependent manner with increased AMPK activity (Fig. 8). Before activation of AMPK, phosphorylation of mTOR and p70S6 kinase was increased. After activation of AMPK, however, time- and dose-dependent decreases in mTOR and p70S6 kinase phosphorylation were observed in the LA-treated C2C12 myotubes. However, 4E-BP1 phosphorylation was not altered by time or dosage.

4. Discussion

In the present study, we demonstrated that oral intake of α-LA improved body composition, glucose tolerance, and energy expenditure of the aged mice, which was associated with increased mitochondrial biogenesis in the skeletal muscle. It is well known that the aging in humans is associated with increased fat mass, declined lean mass [19,27], and decreased basal metabolic rate [28]. Previous studies have demonstrated that dietary LA increases whole-body energy expenditure in adult mice [10]; however, our data are the first to show that LA had the same metabolic action in aged mice. Moreover, this LA-mediated effect on energy metabolism appears to be mediated partially by increased mitochondrial biogenesis in the skeletal muscle. As a result, oral intake of LA might decrease body fat accumulation and increase glucose utilization in the aging mice. However, it should be pointed out that oral intake of LA also increased body protein loss possibly by decreasing protein synthesis. Overall, LA might facilitate the whole-body energy catabolism and glucose utilization in the aged mice.

One of our major findings in the present study is that oral intake of LA increased mitochondrial biogenesis in the skeletal muscle. Brown adipose tissue in small mammals makes the largest contribution toward adaptive thermogenesis. Because humans have relatively little brown fat, however, this effect might thus have limited clinical relevance. In contrast, the skeletal muscle in large adult mammals is a major determinant of energy expenditure [29].
Thus, it is critical to establish whether LA has any beneficial outcomes in the skeletal muscle. In agreement with previous reports [19], our data showed that LA activated AMPK in the skeletal muscle. As a cellular energy sensor, activation of AMPK in peripheral tissues stimulates glucose uptake through initiated GLUT-4 translocation and enhanced GLUT-4 expression [30,31], and increases fatty acid oxidation by inhibiting the activity of acetyl coenzyme A carboxylase [32,33]. We note that PGC-1α is not only a key transcriptional coactivator, but also a major regulator of energy metabolism [34,35]. Forced overexpression of PGC-1α in the skeletal muscle dramatically increases mitochondrial respiration and elevates GLUT-4 transcript levels [36]. In contrast, PGC-1α−deficient mice have diminished mitochondrial number and respiratory capacity in slow-twitch skeletal muscle [34]. Notably, PGC-1α expression is decreased in the skeletal muscle of aged mice [37,38]. In the present study, we show that LA increases mRNA expression of PGC-1α and GLUT-4 in the skeletal muscle of aged mice, which might account for improved glucose homeostasis. Moreover, LA increases the skeletal muscle mitochondrial respiration in aged rats [39]. We note that caloric restriction has been shown to increase longevity and mitochondrial biogenesis [40]. Thus, increased biogenesis of mitochondria could be attributed to LA-specific metabolic action and decreased intake of energy as well. In addition to suppression of AMPK activity in the hypothalamus, however, LA−increased energy expenditure is partially through augmentation of AMPK activity in the skeletal muscle, which increases energy fuel (substrate) oxidation and results in reduced whole-body adiposity. Our data on cultured C2C12 cells not only support this notion, but also agree with those published previously [20]. Most recently, AMPK has been shown to stimulate mitochondrial biogenesis through up-regulating PGC-1α [41]. Therefore, it appears that LA−mediated metabolic phenomenon is mediated partially through activation of AMPK–PGC-1α signaling in the skeletal muscle.

Lipoic acid−mediated loss of BW and improvement in glucose tolerance might be related to suppression of food intake. The evidence that LA stimulated energy expenditure even under suppression of food intake, however, indicates LA−mediated metabolic effects probably independent of reduced food intake in the present study. It should be pointed out that LA−mediated metabolic effects might be dose dependent. As demonstrated previously [10], daily intake of dietary LA (0.5%−1%, equivalent to ~500 mg/kg BW^{0.75}) not only inhibits food intake, but also stimulates energy expenditure in pair-fed, 3-week treatments. In the present study, daily intake of water was estimated at 5.5 mL/d (=BW^{0.667} × 60 mL/kg BW^{0.667} per day) [42]. Thus, the daily intake of LA through 0.75% in drinking water would be approximately 550 mg/kg BW^{0.75}. Adenosine monophosphate−activated protein kinase, as a metabolic “fuel gauge” that oscillates between anabolic and catabolic metabolism, integrates nutritional and hormonal signals to regulate food intake and energy metabolism. Dominant negative AMPK expression in the hypothalamus is sufficient to reduce food intake and BW, whereas constitutively active AMPK increases both [43]. Importantly, energy expenditure is increased not only by stimulation of AMPK activity in peripheral tissues but also by suppression of it in the hypothalamus. Note that the hypothalamus coordinates signals from peripheral tissues to control energy homeostasis. It seems that LA−mediated increase in the whole-body energy expenditure might be mainly due to its modulation of the hypothalamic function. In addition to direct effects on the muscle, LA inhibited the hypothalamic activity of AMPK to promote negative energy balance [10]. However, further studies are warranted to define LA−mediated central vs peripheral actions using tissue-specific AMPK deficiency mouse models. Therefore, LA−mediated metabolic effects in the present study might not only result from suppression of food intake, but also stimulation of energy expenditure, which is regulated by LA−mediated AMPK signaling in the hypothalamus and peripheral tissues (such as muscle, adipose tissue, and liver). Notably, there was a reduction in lean mass in LA−treated mice. Because of a greater loss in fat mass, however, lean mass expressed as the percentage of body composition actually increased in the LA−treated mice. It is unclear whether LA−mediated loss of lean mass resulted from increased rates of protein degradation and/or decreased rates of protein synthesis. The mTOR (a nutrient sensor) regulates cell growth and survival and controls protein synthesis. Phosphorylation of both mTOR and p70S6 kinase decreased in the skeletal muscle of the LA−treated mice, probably indicating decreased protein synthesis. Consistent with this, protein synthesis was suppressed in LA−treated C2C12 cells. Importantly, activation of AMPK by 5−aminoimidazole−4−carboxamide−1−β−D−ribofuranoside appears to suppress protein synthesis in rat skeletal muscle through down-regulating mTOR signaling [44,45]. Thus, LA might suppress protein synthesis in the skeletal muscle, probably resulting from activated AMPK−mediated suppression of the mTOR signaling pathway. Further studies are warranted to establish how LA down−regulates the mTOR signaling involved in protein and energy metabolism to optimize an LA−based treatment for the management of the metabolic syndrome, which might offer the maximum benefit on energy expenditure and glucose metabolism with the minimum loss of lean body mass.

Body fat mass (especially visceral fat) tends to increase with increasing age, whereas physical activity energy expenditure tends to decrease. Reduced levels of physical activity energy expenditure might be attributed to obesity in the older persons. Lipoic acid improved glucose tolerance and energy expenditure (possibly through increasing mitochondrial biogenesis in the skeletal muscle), suggesting that oral intake of LA is able to restore reduced oxidative phosphorylation in the older persons. Thus, the results here may provide further insight into LA−mediated metabolic benefits and potential treatment in older patients who suffer
from obesity and/or insulin resistance. However, it would be better to compare LA-mediated beneficial metabolic effects on aged animals with those on young ones. Thus, a lack of this comparison is a pitfall in the present study. A complete factorial design, that is, 2 ages (young vs old) × 2 treatments (vehicle vs LA) should be used in future studies to address LA-mediated age-specific beneficial effects, if any.

In summary, our present study has demonstrated that LA increased energy expenditure in the skeletal muscle of aged mice partially through enhancing AMPK–PGC-1α–mediated mitochondrial biogenesis and function. Moreover, LA increases lean mass loss possibly by suppressing protein synthesis in the skeletal muscle, which might be attributed to LA-activated AMPK–PGC-1α–mediated down-regulation of the mTOR signaling pathway. With beneficial metabolic actions, LA may be a promising supplement for treatment of obesity and/or insulin resistance in older patients.

Acknowledgment

The authors thank Qiang Tong, Douglas Burrin, Nancy Butte, and Adam Gillum at Baylor College of Medicine for scientific and technical support. This work is supported by the US Department of Agriculture (USDA)/Agricultural Research Service under Cooperative Agreement No. 6250-51000-043 and National Institutes of Health grants 5K01DK75489 (XG) and HL51586 (LC). This work is a publication of the USDA/Agricultural Research Service Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, and Texas Children’s Hospital, Houston, TX. The contents of this publication do not necessarily reflect the views or policies of the USDA; nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

References


